AR001036A1 - Procedimiento para preparar compuestos de fenoxi -2- fenilnaftilo y compuestos intermediarios de aplicacion exclusiva en dicho procedimiento - Google Patents
Procedimiento para preparar compuestos de fenoxi -2- fenilnaftilo y compuestos intermediarios de aplicacion exclusiva en dicho procedimientoInfo
- Publication number
- AR001036A1 AR001036A1 ARP960101524A AR10152496A AR001036A1 AR 001036 A1 AR001036 A1 AR 001036A1 AR P960101524 A ARP960101524 A AR P960101524A AR 10152496 A AR10152496 A AR 10152496A AR 001036 A1 AR001036 A1 AR 001036A1
- Authority
- AR
- Argentina
- Prior art keywords
- procedure
- compounds
- phenylnaphyllum
- exclusive application
- prepare
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
- C07C43/295—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Steroid Compounds (AREA)
Abstract
Se trata de la preparación de compuestos de fenoxi-2-fenilnaftilo de fórmula (I), a partir de intermediarios de fórmula (II), donde R1a es -H u -OR5en el que R5 es un grupo protector de hidroxi, R2a es -H, halógeno u -OR6, en el que R6 esun grupo protector de hidroxi, y R4 es -OH o -CHO, y una de lassales farmacéuticamente aceptables del mismo, útiles para aliviar los síntomas del síndrome postmenopáusico y cáncer hormonadependiente. También sereinvidican dichos intermediarios defórm ula (II)>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/395,950 US5998401A (en) | 1995-02-28 | 1995-02-28 | Naphthyl compounds, intermediates, compositions, and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
AR001036A1 true AR001036A1 (es) | 1997-08-27 |
Family
ID=23565221
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960101524A AR001036A1 (es) | 1995-02-28 | 1996-02-26 | Procedimiento para preparar compuestos de fenoxi -2- fenilnaftilo y compuestos intermediarios de aplicacion exclusiva en dicho procedimiento |
ARP960101525A AR002964A1 (es) | 1995-02-28 | 1996-02-26 | Compuestos de 1(4-hidroxifenil)-2-fenoxi-naftilo, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y compuestosintermediarios de aplicacion en dicho procedimiento. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960101525A AR002964A1 (es) | 1995-02-28 | 1996-02-26 | Compuestos de 1(4-hidroxifenil)-2-fenoxi-naftilo, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y compuestosintermediarios de aplicacion en dicho procedimiento. |
Country Status (32)
Country | Link |
---|---|
US (5) | US5998401A (es) |
EP (1) | EP0729951B1 (es) |
JP (1) | JPH08268881A (es) |
KR (1) | KR960030938A (es) |
CN (2) | CN1053886C (es) |
AR (2) | AR001036A1 (es) |
AT (1) | ATE180776T1 (es) |
AU (1) | AU694837B2 (es) |
BR (1) | BR9600821A (es) |
CA (1) | CA2170337A1 (es) |
CO (1) | CO4700421A1 (es) |
CY (1) | CY2178B1 (es) |
CZ (1) | CZ288213B6 (es) |
DE (1) | DE69602638T2 (es) |
DK (1) | DK0729951T3 (es) |
ES (1) | ES2132841T3 (es) |
FI (1) | FI115524B (es) |
GR (1) | GR3030407T3 (es) |
IL (1) | IL117168A (es) |
IN (1) | IN182138B (es) |
MX (1) | MX9600743A (es) |
MY (1) | MY113232A (es) |
NO (1) | NO305833B1 (es) |
NZ (1) | NZ286072A (es) |
PE (1) | PE28497A1 (es) |
PL (1) | PL183578B1 (es) |
RU (1) | RU2167849C2 (es) |
SG (1) | SG55098A1 (es) |
TR (1) | TR199600126A1 (es) |
TW (1) | TW349946B (es) |
YU (1) | YU11496A (es) |
ZA (1) | ZA961291B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919800A (en) * | 1995-02-28 | 1999-07-06 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
US5856339A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
US5998401A (en) * | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
US5856340A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Method of treating estrogen dependent cancers |
ID19392A (id) * | 1996-08-29 | 1998-07-09 | Lilly Co Eli | Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan |
SI0826679T1 (en) * | 1996-08-29 | 2002-04-30 | Eli Lilly And Company | Naphthyl compounds and compositions |
CA2213814A1 (en) * | 1996-08-29 | 1998-02-28 | Henry Uhlman Bryant | Naphthalene compounds, intermediates, formulations, and methods |
CA2214931A1 (en) * | 1996-09-26 | 1998-03-26 | Henry Uhlman Bryant | Tetrahydrobenzo-a-fluorene compounds and method of use |
CA2214929A1 (en) * | 1996-09-26 | 1998-03-26 | Charles Willis Lugar, Iii | Naphthofluorene compounds, intermediates, compositions and methods |
CA2214935A1 (en) * | 1996-09-26 | 1998-03-26 | Henry Uhlman Bryant | Benzofluorene compounds, intermediates, compositions, and methods |
CA2217810A1 (en) * | 1996-10-10 | 1998-04-10 | Eli Lilly And Company | 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods |
US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
IT1298159B1 (it) * | 1997-01-28 | 1999-12-20 | Hoffmann La Roche | Derivati di un 5-aroilnaftalene |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
CA2298651A1 (en) | 1997-08-07 | 1999-02-18 | Jeffrey Alan Dodge | 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity |
US6107346A (en) * | 1997-08-11 | 2000-08-22 | Eli Lilly And Company | Methods for treating hyperlipidemia |
US5929090A (en) * | 1997-09-12 | 1999-07-27 | Eli Lilly And Company | 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods |
CN1358091A (zh) | 1999-04-16 | 2002-07-10 | 阿斯特拉曾尼卡有限公司 | 雌激素受体-β配体 |
US6312474B1 (en) * | 1999-09-15 | 2001-11-06 | Bio-Vascular, Inc. | Resorbable implant materials |
KR100370597B1 (ko) * | 2000-06-22 | 2003-02-05 | 박정일 | 산형매립초로부터 분리한 신규한 나프탈렌계 화합물 및이를 유효성분으로 하는 약학적 조성물 |
AU2002228595A1 (en) * | 2000-11-28 | 2002-06-11 | Eli Lilly And Company | Synthesis of 2-aryl-1-naphthol derivatives via a tandem palladium catalyzed arylation and dehydrogenation |
EP1395563B1 (en) | 2001-05-22 | 2006-03-29 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
ES2236536T3 (es) * | 2001-05-22 | 2005-07-16 | Eli Lilly And Company | Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos. |
TWI306450B (en) | 2001-12-13 | 2009-02-21 | Wyeth Corp | Substituted phenyl naphthalenes as estrogenic agents |
PL374845A1 (en) | 2002-07-22 | 2005-11-14 | Eli Lilly And Company | Selective estrogen receptor modulators containing a phenylsulfonyl group |
US9315539B2 (en) * | 2002-10-01 | 2016-04-19 | Yale University | 11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer |
MXPA05009098A (es) | 2003-02-25 | 2005-11-17 | Lilly Co Eli | Clorhidrato de 1- (4-(2 -piperidiniletoxifenoxi) -2-(4-metansulfonilfenil) -6-hidroxinaftaleno cristalino no solvatado. |
NZ541126A (en) * | 2003-02-25 | 2008-07-31 | Lilly Co Eli | Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride |
US20040253319A1 (en) * | 2003-06-11 | 2004-12-16 | Shrirang Netke | Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy |
JP4589337B2 (ja) * | 2003-11-20 | 2010-12-01 | イーライ リリー アンド カンパニー | ビタミン受容体調節剤 |
WO2005051898A2 (en) * | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
CN1910167B (zh) * | 2004-01-22 | 2011-08-10 | 伊莱利利公司 | 用于治疗血管舒缩症状的选择性雌激素受体调节剂 |
EP1709023B1 (en) | 2004-01-22 | 2009-11-11 | Eli Lilly And Company | Selective estrogen receptor modulators |
BRPI0506721A (pt) * | 2004-01-22 | 2007-05-02 | Lilly Co Eli | composto ou um sal de adição de ácido do mesmo |
MXPA06015152A (es) * | 2004-06-22 | 2007-02-28 | Smithkline Beecham Corp | Compuestos quimicos. |
EP2342189A2 (en) * | 2008-09-29 | 2011-07-13 | Eli Lilly And Company | Selective estrogen receptor modulator for the treatment of osteoarthritis |
BR112012032189B1 (pt) | 2010-06-16 | 2020-11-03 | Endorecherche, Inc | usos de um agonista ou antagonista de lhrh em associação com um modulador de receptor de estrogênio seletivo e com um precursor de esteróide sexual para a preparação de uma medicamento para o tratamento ou prevenção de doenças relacionadas com estrogênio e kits |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3274213A (en) * | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
US3396169A (en) * | 1966-10-26 | 1968-08-06 | Upjohn Co | Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes |
US3862232A (en) * | 1963-07-03 | 1975-01-21 | Upjohn Co | 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof |
US3313853A (en) * | 1963-10-16 | 1967-04-11 | Upjohn Co | 2-(tertiaryaminoalkoxyphenyl)-3, 4-dihydronaphthalenes and 2-(tertiaryaminoalkoxyphenyl) -3, 4- dihydro -1(2h)-naphthalenones |
US3293263A (en) * | 1963-12-09 | 1966-12-20 | Upjohn Co | Diphenylbenzocycloalkenes |
US3320271A (en) * | 1964-06-01 | 1967-05-16 | Upjohn Co | 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes |
GB1138163A (en) * | 1965-05-21 | 1968-12-27 | Bristol Myers Co | Benzothiophene derivatives having anti-fertility properties |
US3394125A (en) * | 1965-10-23 | 1968-07-23 | Bristol Myers Co | 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group |
US3483293A (en) * | 1967-12-15 | 1969-12-09 | Upjohn Co | Method for controlling birds and rodents |
US3567737A (en) * | 1968-01-02 | 1971-03-02 | Upjohn Co | Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes |
US3862323A (en) | 1971-09-20 | 1975-01-21 | Betz Laboratories | Dioxide slime control composition and its use |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4400543A (en) * | 1975-10-28 | 1983-08-23 | Eli Lilly And Company | 3-Phenyl-4-benzoyl-1,2-dihydronaphthalenes |
US4230862A (en) * | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
DE3121175A1 (de) * | 1981-05-27 | 1982-12-16 | Klinge Pharma GmbH, 8000 München | Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
GB8311678D0 (en) * | 1983-04-28 | 1983-06-02 | Ici Plc | Phenol derivatives |
GB8705174D0 (en) * | 1987-03-05 | 1987-04-08 | Ici Plc | Heterocyclic compounds |
US5013761A (en) * | 1988-06-03 | 1991-05-07 | Eli Lilly And Company | Serotonin antagonists |
FR2665444B1 (fr) | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
US5254568A (en) * | 1990-08-09 | 1993-10-19 | Council Of Scientific & Industrial Research | Benzopyrans as antiestrogenic agents |
DE4117512A1 (de) | 1991-05-25 | 1992-11-26 | Schering Ag | 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
US5147880A (en) * | 1991-07-22 | 1992-09-15 | Eli Lilly And Company | Benzo[a]fluorene compounds |
AU672182B2 (en) * | 1991-11-27 | 1996-09-26 | Novo Nordisk A/S | Piperidine derivatives and their use in treating psychosis |
US5424334A (en) | 1991-12-19 | 1995-06-13 | G. D. Searle & Co. | Peptide mimetic compounds useful as platelet aggregation inhibitors |
US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US7501441B1 (en) * | 1994-09-20 | 2009-03-10 | Eli Lilly And Company | Naphthyl compounds, intermediates, processes, compositions, and methods |
US5510357A (en) | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
US5998401A (en) * | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
-
1995
- 1995-02-28 US US08/395,950 patent/US5998401A/en not_active Expired - Fee Related
- 1995-06-06 US US08/465,844 patent/US5574190A/en not_active Expired - Fee Related
- 1995-06-06 US US08/469,971 patent/US5567712A/en not_active Expired - Fee Related
- 1995-06-06 US US08/466,954 patent/US6268361B1/en not_active Expired - Fee Related
-
1996
- 1996-02-09 ES ES96300877T patent/ES2132841T3/es not_active Expired - Lifetime
- 1996-02-09 DE DE69602638T patent/DE69602638T2/de not_active Expired - Fee Related
- 1996-02-09 AT AT96300877T patent/ATE180776T1/de not_active IP Right Cessation
- 1996-02-09 DK DK96300877T patent/DK0729951T3/da active
- 1996-02-09 EP EP96300877A patent/EP0729951B1/en not_active Expired - Lifetime
- 1996-02-15 TW TW085101903A patent/TW349946B/zh active
- 1996-02-15 PL PL96312829A patent/PL183578B1/pl unknown
- 1996-02-16 TR TR96/00126A patent/TR199600126A1/xx unknown
- 1996-02-19 ZA ZA9601291A patent/ZA961291B/xx unknown
- 1996-02-19 IL IL11716896A patent/IL117168A/en not_active IP Right Cessation
- 1996-02-22 IN IN321CA1996 patent/IN182138B/en unknown
- 1996-02-26 FI FI960889A patent/FI115524B/fi active IP Right Grant
- 1996-02-26 AU AU45732/96A patent/AU694837B2/en not_active Ceased
- 1996-02-26 PE PE1996000130A patent/PE28497A1/es not_active Application Discontinuation
- 1996-02-26 JP JP8037970A patent/JPH08268881A/ja active Pending
- 1996-02-26 RU RU96103632/04A patent/RU2167849C2/ru active
- 1996-02-26 KR KR1019960004619A patent/KR960030938A/ko not_active Application Discontinuation
- 1996-02-26 CN CN96105727A patent/CN1053886C/zh not_active Expired - Fee Related
- 1996-02-26 CZ CZ1996581A patent/CZ288213B6/cs not_active IP Right Cessation
- 1996-02-26 MX MX9600743A patent/MX9600743A/es not_active IP Right Cessation
- 1996-02-26 NO NO960772A patent/NO305833B1/no not_active IP Right Cessation
- 1996-02-26 CO CO96008862A patent/CO4700421A1/es unknown
- 1996-02-26 CA CA002170337A patent/CA2170337A1/en not_active Abandoned
- 1996-02-26 AR ARP960101524A patent/AR001036A1/es active IP Right Grant
- 1996-02-26 BR BR9600821A patent/BR9600821A/pt not_active Application Discontinuation
- 1996-02-26 AR ARP960101525A patent/AR002964A1/es unknown
- 1996-02-26 YU YU11496A patent/YU11496A/sh unknown
- 1996-02-26 NZ NZ286072A patent/NZ286072A/en unknown
- 1996-02-27 SG SG1996006121A patent/SG55098A1/en unknown
- 1996-02-27 MY MYPI96000686A patent/MY113232A/en unknown
-
1999
- 1999-06-03 GR GR990401445T patent/GR3030407T3/el unknown
- 1999-11-05 CN CNB99123572XA patent/CN1152683C/zh not_active Expired - Fee Related
-
2000
- 2000-05-03 US US09/563,282 patent/US6355632B1/en not_active Expired - Fee Related
- 2000-08-02 CY CY0000035A patent/CY2178B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR001036A1 (es) | Procedimiento para preparar compuestos de fenoxi -2- fenilnaftilo y compuestos intermediarios de aplicacion exclusiva en dicho procedimiento | |
PT96897A (pt) | Processo para a preparacao de novos compostos aril-e heteroariletilenicos e de composicoes farmaceuticas que os contem | |
KR870003782A (ko) | 활성성분으로서 2-알키닐아데노신을 함유하는 항고혈압제 | |
KR910015568A (ko) | 신경 보호성 3-피페리디노-4-하이드록시 크로만 유도체 | |
ES2083438T3 (es) | Procedimiento para la preparacion de taxol utilizando una oxazinona. | |
BR9916772A (pt) | Quinolinacarboxamidas como agentes antivirais | |
CA2420996A1 (en) | Substituted heterocyclic compounds for treating multidrug resistance | |
MX9302214A (es) | Derivados de taxol y proceso para su preparacion | |
CO5210864A1 (es) | Nuevos derivados de bencimidazolonas que tienen afinidad para receptores mezclados de serotonina y dopamina | |
TW336939B (en) | Lipopeptide derivatives, a process for their preparation and their use | |
ES2155566T3 (es) | Uso de derivados de rifamicina para el tratamiento de enfermedades infecciosas por clamidia. | |
BR9808486A (pt) | Processo para a preparação de um composto | |
YU53402A (sh) | Preparat | |
KR950004377A (ko) | 안트라센 유도체 | |
CO4700291A1 (es) | Compuestos quimicos | |
ES2185967T3 (es) | Procedimiento para preparar derivados acidos beta-amino-alfa-hidroxi. | |
JPS51140465A (en) | Compensating lens | |
BR9911250A (pt) | Processo para preparação de compostos | |
FI892991A (fi) | Nya 4,5,7,8-tetrahydro-6h-tiazolo/5,4-d /azepiner, deras framstaellning och deras anvaendning som laekemedel. | |
KR950700233A (ko) | 아미노산 유도체 및 항활성산소제(Amino acid derivatives and anti-active oxygen agents) | |
SE9002596D0 (sv) | A method for synthesis of prostaglandin derivatives | |
ES2172768T3 (es) | Procedimiento para preparar un compuesto de fosfito multidentado. | |
KR910009271A (ko) | 15-케토-프로스타글란딘 화합물을 이용한 폐 부전증의 치료 | |
DK257083D0 (da) | Mikroorganismestammen chromobacterium violaceum, farmaceutisk aktive forbindelser fremstillet med stammen, fremgangsmade til fremstilling af forbindelserne og disses anvendelse som laegemidler | |
BR0015122A (pt) | Composição farmacêutica, e, método de tratamento de inflamação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |